<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240070</url>
  </required_header>
  <id_info>
    <org_study_id>MINDIT2000</org_study_id>
    <nct_id>NCT01240070</nct_id>
  </id_info>
  <brief_title>Multifactorial Intervention in Type 2 Diabetes - Italy</brief_title>
  <acronym>MINDIT</acronym>
  <official_title>Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Society of Diabetology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Parma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite several clinical trials have clearly demonstrated that the correction of a single
      cardiovascular risk factor in patients with type 2 diabetes decreases the incidence of
      myocardial infarction and other cardiovascular disease (CVD) events, only the Steno study has
      been evaluating the effect of a multifactorial intervention strategy on macrovascular
      complications of diabetes. For this reason, the disease management approach currently
      endorsed by international guidelines (i.e correction of all major CVD risk factors to target
      levels usually lower than lower risk populations) has not been extensively investigated in
      terms of prevalence of application in current clinical practice and in terms of real
      efficacy.

      The Multifactorial INtervention in type 2 Diabetes - ITaly (MIND.IT) is a multicentric
      two-phase study involving 9 Diabetes Care Units throughout Italy with the overall aims of:
      (1) investigating the degree of application of the international guidelines for CVD
      prevention in type 2 diabetic patients and (2) verifying whether the application of an
      intensive multi-factorial intervention inspired by these guidelines is feasible and effective
      in decreasing the incidence of new CVD events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is multi-centric, randomized, open label, active treatment controlled, two
      parallel-group, pragmatical intervention trial with 5 years of follow-up, to assess
      superiority of an intensive treat-to-target strategy (including lifestyle and pharmacological
      interventions) for correction of major cardiovascular risk factors compared to usual care in
      decreasing incidence of first cardiovascular events in non complicated type 2 diabetic
      patients at high risk, as defined by presence of 2 or more cardiovascular risk factors. All
      high-risk patients identified during phase 1 who accepted to participated were allocated to
      usual or intensive treatment based on the recruiting center. Centers were randomly assigned
      to treatment arm before phase 2 beginning. Investigators from Intensive Care centers received
      centralized training to ensure the application of the intensive care program on their
      patients.

      HbA1c values and lipid profile are assessed in peripheral laboratories (one per each study
      site) with an external, centralized, quality control program and the adjustment for
      systematic differences among study labs.

      Participating investigators are left free to decide upon patient's treatments. In
      intensive-care centers, investigators are provided with a multi-factorial step-wise protocol
      to support the application of a treat-to-target approach. Intensive care strategy includes
      intervention on lifestyle.

      Dietary intervention goals: BMI&lt;25 or 5% reduction of body weight; dietary assumption of
      saturated fat &lt;10% of total caloric intake; fibers= 15-20 g/1000 Kcal. Methods defined to
      reach the dietary goal: A) Patients with BMI 25-30 kg/m2: reduction of caloric intake =
      300-500 Cal/d; B) Patients with BMI &gt;30: reduction of caloric intake 500-800 Cal/d.

      Physical activity intervention goal: 200-300 calories per day. Example: brisk walking for 30
      min every day or biking (18-25Km/h 45-60 min). Alternatives: swimming 1h , dancing 1h, gym
      exercise 1h;-avoiding isometric exercise and exercise with intensity &gt;50-60 % of maximal
      oxygen consumption. Frequency: everyday or at least 3 times a week; Pharmacological
      intervention: Blood glucose control, multi-step intervention. In obese patients: 1) Metformin
      (M, 500-2500mg); 2) M+Sulphonylureas (S) or S-like drugs, increasing progressively the dose;
      3) M+S+Acarbose; 4) M+S+insulin bed-time; 5) insulin basal-bolus. In normal weight patients:
      1) S; 2) S+acarbose; 3) S+ bed-time insulin; 4) insulin basal bolus; Blood pressure control
      --&gt; 1) Ace-inhibitors or AT-II receptor antagonists; 2) add long acting calcium-channel
      blockers or beta-blockers or low dose diuretics; 3) add a third drug; lipid control: 1) diet
      + physical activity; 2) if LDL &gt; 130 mg/dL statins (with a stepwise increase of dose if
      necessary); if triglycerides &gt; 200 mg/dL fibrates; anti-platelet treatment: aspirin 100 mg/d
      in all patients (alternative drugs for aspirin-intolerants).

      The scheduled visits were defined as follows:

        -  Intensive-care group: mandatory visit every three months with annual visit for MIND.IT
           data collection.

        -  Usual-care group: at least one MIND.IT visit every year + the usual organization of the
           center.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2002</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>5 years of follow up</time_frame>
    <description>To verify if an intensive care intervention compared to usual care is able to significantly decrease the incidence of first cardiovascular event. Composite primary end-point = mortality for cardiovascular causes, proven acute myocardial infarction (STEMI or NSTEMI), acute coronary syndrome requiring hospitalization, proven ischemic stroke, coronary or carotid revascularization procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular risk factors changes</measure>
    <time_frame>2 years and 5 years of follow up</time_frame>
    <description>To assess whether the intensive treatment is able to significantly improve cardiovascular risk factors with increased multiple-target achievement. A pre-planned interim analysis after two years of follow-up was foreseen by the study protocol.
To verify that the intesive protocol implemented on the basis of national and international guidelines is actually feasible in a real world clinical setting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1461</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinical practice in type 2 diabetes treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive care</intervention_name>
    <description>Intensive multi-factorial treat-to-target intervention program designed according to international guidelines</description>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_label>Intensive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders

          -  age 50-70 years

          -  Type two diabetes with at least two-year history of disease and without insulin
             treatment in the first two years after diagnosis

          -  Negative medical history for documented previous cardiovascular events or
             macrovascular complications

          -  Written consent to participate

          -  Presence of at least 2 of the following risk factors:

               -  LDL cholesterol &gt; 130 mg/dL (regardless of treatment)

               -  Triglycerides &gt; 200 mg/dL

               -  HDL cholesterol &lt; 35 (males) or 45 (females) mg/dL

               -  Blood pressure &gt; 140/90 mmHg

               -  Cigarette smoking

        Exclusion Criteria:

          -  Age below 50 or above 70 years

          -  Type 1 diabetes, diagnosis before 40 years of age, known presence of auto-antibodies
             or insulin requirement in the first 2 years of disease.

          -  Chronic kidney failure (plasma creatinine &gt; 2 mg/dL)

          -  Significant liver damage (AST and/or ALT &gt; 2 times the upper limits of normality)

          -  History of previous cardiovascular events

          -  Active neoplasms or any concomitant disease limiting life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana Zavaroni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Parma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela A Rivellese, MD</last_name>
    <role>Study Director</role>
    <affiliation>Federico II University of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Vaccaro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Federico II University of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Miccoli, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariella Trovati, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Cavalot, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Boemi, MD</last_name>
    <role>Study Director</role>
    <affiliation>INRCA of Ancona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PierPaolo DeFeo, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Of Perugia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Francesco Giorgino</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Dolci</name>
      <address>
        <city>Carrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lamberto De Giorgio</name>
      <address>
        <city>La Spezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giuseppe Derosa</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PierPaolo DeFeo</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donatella Zavaroni</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roberto Miccoli</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giovanni Ghirlanda</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mariela Trovati</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rivellese AA, Boemi M, Cavalot F, Costagliola L, De Feo P, Miccoli R, Patti L, Trovati M, Vaccaro O, Zavaroni I; Mind.it Study Group. Dietary habits in type II diabetes mellitus: how is adherence to dietary recommendations? Eur J Clin Nutr. 2008 May;62(5):660-4. Epub 2007 Apr 11.</citation>
    <PMID>17426738</PMID>
  </reference>
  <reference>
    <citation>Vaccaro O, Boemi M, Cavalot F, De Feo P, Miccoli R, Patti L, Rivellese AA, Trovati M, Ardig√≤ D, Zavaroni I; MIND-IT Study Group. The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy. Atherosclerosis. 2008 Jun;198(2):396-402. Epub 2008 Feb 21.</citation>
    <PMID>18093594</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>August 11, 2011</last_update_submitted>
  <last_update_submitted_qc>August 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>FoRiSID, Research Foundation of the Italian Society of Diabetology</name_title>
    <organization>Italian Society of Diabetology</organization>
  </responsible_party>
  <keyword>diabetes,</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>risk factor</keyword>
  <keyword>cardiovascular event</keyword>
  <keyword>intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

